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Introduction
Cajanus cajan (cajanine) is a perennial legume from the family Fabaceae. 1 It is extracted from pigeon pea leaves and has been reported to exhibit a variety of bioactivities, including antimalaria, hypolipidemia and cytotoxicity effects, as well as reducing bone loss and promoting bone-like tissue formation. [1] [2] [3] [4] [5] [6] [7] Moreover, a recent study revealed that cajanine could increase tibial bone density and improve bone metabolism as well as lipid metabolism in ob/ob mice with osteoporosis and hyperlipidemia symptoms, indicating that cajanine might be a promising drug candidate due to its broad range of bioactivities. 8 Mesenchymal stem cells (MSCs) are a small population of multipotent stromal cells that are present in practically all tissues. 9 Mesenchymal stem cells are maintained in a relative state of quiescence in vivo; however, they are capable of proliferating and then differentiating into osteoblasts, chondrocytes, adipocytes, or other mesoderm-type lineages when stimulated by a variety of physiological and pathological signals. 9 Multiple signaling networks have been demonstrated for the development and differentiation of MSCs into functional mesenchymal lineages. The transforming growth factor-β (TGF-β) signal pathway has been studied as a key regulator in the self-renewal, maintenance and differentiation of stem cells. [10] [11] [12] It has been reported that TGF-β1 plays an important role in cartilage development and is an important chondrogenic factor. 12, 13 Moreover, some studies have demonstrated that cajanine has anti-tumor and anti-oxidant functions.
14 Despite evidence revealing that cajanine has potential to be a therapeutic agent, the detailed mechanisms of anti-tumor effects are still under investigation.
In this study, the roles of cajanine in the proliferation and differentiation of bone marrow MSCs (BMSCs) were investigated. The osteogenesis markers and cell cycle were further assessed.
Material and methods

Bone marrow mesenchymal stem cells culture
Human bone marrow aspirates were obtained from donors from Dongzhimen Hospital, Beijing, China, in the years 2012-2014, and isolated by density gradient centrifugation, utilizing Ficoll-Paque TM PLUS solution (GE Healthcare, Uppsala, Sweden), followed by cell-surface marker negative selection according to the previous report. 15 Bone marrow MSCs isolated from donors were used within 4 passages. Briefly, cells were harvested using 0.25% trypsin with 1.0 M ethylenediaminetetraacetic acid (EDTA), centrifuged and expanded in basal medium, consisting of high-glucose Dulbecco's Modified Eagle's Medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 100 unit/mL penicillin and 100 unit/mL streptomycin (basal medium). Basal medium contained high-glucose DMEM, FBS, penicillin and streptomycin (all from Gibco, Gaithersburg, USA). Cells were maintained in a 37°C incubator. The medium was changed every 3 days. 
Chemicals and antibodies
Osteogenic induction
Osteogenic differentiation was performed by culturing 3 × 10 4 human BMSCs (hBMSCs) in a 6-well plate in Poietics ® osteogenic induction medium (Lonza Walkersville, Inc., Walkersville, USA), which contained dexamethasone, ascorbic acid and β-glycerophosphate supplements.
Von Kossa staining
The cells were fixed in cold methanol for 15-20 min at −20°C, followed by incubation with 5% silver nitrate solution (ab150687; Abcam), and crosslinked under UV light for 20-30 min, then rinsed twice with distilled water. The dishes were incubated with 5% sodium thiosulfate solution for 2-3 min. After rinsing twice, the dishes were finally incubated with nuclear fast red solution for 5 min, and rinsed with distilled water to remove excess stain.
Real-time polymerase chain reaction
Total RNAs were extracted using the TRIzol ® reagent (Sigma-Aldrich), according to the manufacturer's instructions. After diminishing genomic DNA contamination by Turbo DNAse (Thermo Fisher Scientific, Waltham, USA), according to the manufacturer's instructions, the purified RNA (10 ng/mL) was reverse-transcribed with the High Capacity cDNA Reverse Transcription (RT) Kit (Qiagen, Valencia, USA) under the following conditions: 25°C for 10 min, 37°C for 120 min, followed by 85°C for 5 min. The real-time polymerase chain reaction (RT-PCR) was performed on an Applied Biosystems StepOnePlus TM PCR machine (Applied Biosystems, Foster City, USA), using 5 μL SYBR ® Green PCR Master Mix (Life Technologies, Grand Island, USA), 2 μL sequence specific primers (0.5 mM; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used at the amount of 0.25 mM) and 3 μL cDNA under the following conditions: 95°C for 10 min, followed by 40 cycles of 15 s of denaturation at 95°C and 60 s of annealing and elongation at 60°C. A melting curve analysis was performed after each run to confirm the product specificity. The 2Δ Ct method was employed to determine the relative gene expression level of the gene of interest, normalized to the endogenous controls. 
Cell proliferation assays
Cell proliferation rates were measured by a methylthiazol tetrazolium (MTT) assay, using Cell Proliferation Assay Kit (Thermo Fisher). After the cells were treated with cajanine, MTT was added to each well and the cells were incubated at 37°C for 2 h. The plates were centrifuged at 450 × g for 5 min at room temperature and the medium was removed. To solubilize the crystals, dimethyl sulfoxide (DMSO) was added to each well and the plates were read at 570 nm, using a microplate reader (Molecular Devices, Sunnyvale, USA). The same experiment was repeated 3 times.
Immunofluorescence
The cells were fixed in 4% paraformaldehyde, rinsed with 1× phosphate-buffered saline (PBS) and incubated with 3% bovine serum albumin (BSA) blocking solution for 60 min on a shaker. Runx2 antibody (1:500 dilution) was added directly to the blocking solution and the samples were further incubated for 3 h at room temperature. The samples were washed with 1× PBS and incubated with 5 μL AlexaFluor ® 488-labeled goat anti-rabbit secondary antibody (2 mg/mL; Molecular Probes, Carlsbad, USA) in 1× PBS at room temperature, protected from light. After 60 min of incubation, the cells were washed with 1× PBS for 3 times of 5 min each. 4',6-diamidino-2-phenylindole (DAPI) was added to PBS for nuclear staining at 1 × 5000, followed by washing by PBS. Images were taken with an Olympus IX70 inverted microscope (Olympus, Tokyo, Japan) and processed, using ImageJ software (National Institutes of Health, Bethesda, USA).
Western blot
After the cajanine treatment, the cells were collected and the harvested proteins were first separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and then transferred to nitrocellulose membranes (Bio-Rad Laboratories, Hercules, USA). The membranes were blocked with 5% non-fat milk and incubated with primary antibodies at a dilution of 1:1000. The membranes were subsequently incubated with a horseradish peroxidase secondary antibody (Sigma-Aldrich). The protein complex was detected, using enhanced chemiluminescence reagents (Pierce Biochnology Inc., Rockford, USA). Endogenous α-tubulin was used as the internal control.
Statistical analysis
Statistical analyses were performed with Student's t-test or one-way analysis of variance (ANOVA), using Prism v. 5.0 (GraphPad Software, La Jolla, USA).
Results
Cajanine promotes the osteogenic differentiation of bone marrow mesenchymal stem cells
It has been well recognized that the human bone marrow stroma contains multipotent mesenchymal cells that give rise to adipocytes and osteoblasts, as well as many other lineages. 9 To assess the roles of cajanine in the differentiation of BMSCs, we started to investigate whether cajanine isolated from the plant Cajanus cajan L. Millsp. could regulate the osteogenesis of BMSCs in vitro. Bone marrow MSCs were isolated and cultured with or without cajanine for 24 h, then the cells were cultured in regular osteogenic differentiation medium for 16 days. Interestingly, our results show that BMSCs treated with cajanine achieved dramatic increases in extracellular calcium deposits (Fig. 1) . Consistently, the results described above were confirmed by Von Kossa staining, which is used for histological visualization of calcium deposits. After 3 weeks of osteogenic induction, the cajanine-treated BMSCs displayed higher The data is presented as means ± standard deviations (SD); BMSCs -bone marrow mesenchymal stem cells; MTT -methylthiazol tetrazolium; OD -optical density.
levels of calcine deposit than the control group (Fig. 2) . Taken together, we found that cajanine promoted the osteogenic differentiation of BMSCs.
The effects of in vitro cajanine treatment on the expressions of osteogenesis markers
To investigate the mechanisms of the cajanine-stimulated osteogenesis of BMSCs, we assessed the osteogenic markers. It has been reported that the expressions of osteopontin (OPN) and type I collagen are the markers of osteogenesis. 9 As we expected, BMSCs treated with cajanine showed upregulated expressions of OPN and collage I at protein and mRNA levels (Fig. 3A-D) . Moreover, Runx2, a transcription factor required for bone formation and the differentiation of BMSCs into osteoblasts, is primarily controlled by the activation of Runx2. 16 As we expected, cajanine promoted the nuclear translocation of Runx2 in BMSCs (Fig. 3E) , suggesting that the cajanine-activated BMSCs had higher Runx2 activity.
The proliferation rate of bone marrow mesenchymal stem cells is stimulated by cajanine
We next investigated the effects of cajanine on the proliferation of BMSCs in vitro. Bone marrow MSCs were left untreated or were treated with cajanine at 1, 10 or 100 ng/mL for 3, 6, 9, 12, and 15 days. The MTT assays were performed to measure the cell proliferation ratio. Our data in Table 1 and Fig. 4 demonstrate that cajanine treatment at low concentrations (1 ng/mL) could significantly increase the cell proliferation after 6 days. At higher concentrations (10 and 100 ng/mL), the cell proliferation rates were similar as in the case of low concentrations. Taken together, our results revealed that cajanine promoted both the osteogenic differentiation and proliferation of BMSCs, suggesting cajanine might contribute to the development of therapeutic agents for the clinical applications of tissue engineering.
Cajanine activates cell cycle regulators of bone marrow mesenchymal stem cells
Our abovementioned results demonstrated that cajanine promotes the proliferation of BMSCs in vitro. We then assessed the cell cycle markers of BMSCs in response to cajanine treatment. To determine the cell cycle consequences of cajanine, we analyzed cell cycle regulators in cajaninetreated BMSCs. Interestingly, our data showed that the phosphorylation of retinoblastoma (Rb) is responsible for a major G1 checkpoint, which was increased by cajanine stimulation, suggesting that cajanine might contribute to the G1 to S phase transition (Fig. 5) . In addition, we found that the expressions of CDK2, cyclin B1 and CDC 25A&B were upregulated by cajanine treatment (Fig. 5) , which shows that cajanine promoted the proliferation of BMSCs through the modulation of cell cycle progressions.
Discussion
Cajanus cajan L. Millsp. is a traditional Chinese medicine herb involved in diverse biological processes. In this study, we explored the roles of cajanine in the differentiation and proliferation of hBMSCs. We found that cajanine treatment promoted the osteogenic differentiation of BMSCs in vitro. Since BMSCs are a promising source of precursor cells, which may be applied in various tissue engineering strategies, our study focused on the regulatory functions of cajanine in relation to the osteogenic differentiation of BMSCs, providing a new approach to the development of therapeutic agents for tissue engineering.
Bone marrow MSCs can be induced to differentiate toward a variety of mature target cells by differentiation-specific Bone marrow mesenchymal stem cells treated with a control solution, 1, 10 or 100 ng/mL of cajanine for 3, 6, 9, 12, and 15 days; the cell proliferation rates measured using a MTT assay. BMSCs -bone marrow mesenchymal stem cells; MTT -methylthiazol tetrazolium. protocols. Moreover, bone differentiation and formation are regulated at the molecular level. Previous studies demonstrated that Runx2 is a transcription factor required for bone formation. 17 Runx2 is also a target of bone morphogenetic proteins (BMPs) and is induced by TGF-β in pluripotent mesenchymal precursor cells. 18 Apart from the TGF-β pathway, BMSCs osteogenic differentiation was directed through the non-SMAD signaling pathways, mitogen-activated protein kinase (MAPK) signaling and Wnt signaling cascades. 19 Our results, consistent with the previous studies, showed that the activities of Runx2, as well as other osteogenic markers, are upregulated by cajanine treatment.
Bone marrow MSCs are maintained in a relative state of quiescence until they are activated by a variety of physiological and pathological stimuli. Bone marrow MSCs are capable of proliferating and then differentiating into osteoblasts, chondrocytes, adipocytes, or other mesoderm-type lineages. Therefore, the proliferation of BMSCs is important for maintaining the biological functions of them before differentiation. We report here that cajanine promotes the proliferation of BMSCs by the upregulation of cell cycle regulators. We will continue to explore the detailed mechanisms of the cajanine-stimulated proliferation of BMSCs by measuring other cell proliferation signaling pathways, such as mTOR, Akt or MAPK, in further work. In summary, we discovered a novel function of cajanine in the regulation of osteogenic differentiation and proliferation in BMSCs. Our study will contribute to the cajanine-based drug development for tissue engineering.
